Devonian Health GroupDVHGF 49 Gross Margin % is 6.78% as of Jan. 2026, which is 78% below its 10-year median of 30.31. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $3.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 732 Biotechnology companies, Devonian Health Group ranks worse than 65.71% on this metric.
DVHGF's Gross Margin % is ranked worse than 65.71% of 732
companies
in the Biotechnology industry
Industry Median: 60.91
vs DVHGF: 44.51
Devonian Health Group had a gross margin of 6.78% for the quarter that ended in Jan. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Devonian Health Group was 0.00% per year.
Devonian Health Group (OTCPK:DVHGF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Devonian Health Group had a gross margin of 6.78% for the quarter that ended in Jan. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Devonian Health Group Gross Margin % Related Terms
Devonian Health Group Gross Margin % Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Devonian Health Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Devonian Health Group (DVHGF) has a Gross Margin % of 6.78% as of Jan. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Devonian Health Group and its competitors. This is 78% below median its historical median of 30.31. According to the industry distribution chart, Devonian Health Group ranks #481 out of 732 companies in the Biotechnology industry, placing it in the top 65.7%.
Is Devonian Health Group's Gross Margin % too high?
Devonian Health Group's current Gross Margin % of 6.78% is 78% below median its 10-year median of 30.31. The Biotechnology industry median Gross Margin % is 60.91. Devonian Health Group's value of 6.78% is 88.9% below this industry median. Based on the distribution chart, Devonian Health Group ranks #481 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #481 out of 732 companies for Gross Margin %. This places Devonian Health Group in the lower half of its industry. The industry median Gross Margin % is 60.91. Devonian Health Group's value of 6.78% is 88.9% below this benchmark. While the company's 10-year median is 30.31 vs. the industry median of 60.91, Devonian Health Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devonian Health Group's current Gross Margin % of 6.78% is 88.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Gross Margin % is 6.78%, which is 78% below median its own 10-year median of 30.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $7.00 — trading 131.8% above its estimated fair value. The current Gross Margin % is 6.78%, which is 78% below median its 10-year median of 30.31 and 88.9% below the Biotechnology industry median of 60.91. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Gross Margin % is 6.78% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 131.8% above its estimated GF Value™ of $3.02.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Gross Margin %: 6.78% (78% below median its 10-year median of 30.31)
GF Value™: $3.02 vs. price of $7.00 (131.8% above fair value)
Industry Position: 88.9% below the Biotechnology median (#481 of 732)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
